Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma (HCC) in the first-line setting.
The trial’s primary endpoint was overall survival (OS). The study was based on an earlier randomized phase II trial, which compared the efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo. That phase II trial was conducted prior to sorafenib becoming the standard of care for advanced HCC, Abou-Alfa explains.
In the CALGB 80802 study, median OS with sorafenib monotherapy was 10.5 months versus 9 months with doxorubicin plus sorafenib. These findings did not demonstrate a benefit of adding doxorubicin to sorafenib in this patient population, Abou-Alfa says.
<<<
